ArticleBone marrow transplantation2016

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.

D M Burns et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.